Review a combination of haemodynamic and metabolic mechanisms, growth factors, cytokines and genetic susceptibility linked to the diabetic state per se, as reviewed by several authors. [2] [3] [4] [5] [6] In later stages, haemodynamic and non-haemodynamic renal adaptations follow a common pathway for noxious stimuli in the kidney, which eventually leads to destroyed kidney function if renoprotective treatment is not introduced. 7-10 Activation of the renin-angiotensin system (RAS) is of key importance in both the initiation and the later stages of the diabetic kidney disease.
Elevated systemic BP and albuminuria are the most important non-genetic risk factors for a fast decline in renal function in patients with diabetic nephropathy. 2, [11] [12] [13] In accordance, lowering BP and albuminuria with antihypertensive treatment is the most powerful tool to slow down the progression of diabetic nephropathy. 2, 11 The lower the BP and albuminuria levels after initiation of antihypertensive therapy, especially blockade of the RAS, the better long-term course of diabetic nephropathy. 2, 11, [14] [15] [16] [17] [18] [19] Therefore, reduction in albuminuria after the start of antihypertensive treatment may serve as a surrogate endpoint for monitoring treatment efficacy and long-term prognosis in diabetic nephropathy. 9, 18, 20 Despite a dramatically improved prognosis in diabetic nephropathy over the past 25 years, [21] [22] [23] [24] the current mean loss of glomerular filtration rate (GFR) in Type 1 diabetic patients with diabetic nephropathy is still 3-4 times higher than normal, with a range from 0 and 24 ml/minute/year. 2, 13 As a consequence, some patients will reach dialysis within 5 years of onset of diabetic nephropathy, whereas others will die with well-preserved kidney function. Therefore, major determinants of the course of diabetic nephropathy (risk factors) are still to be described in order to understand the pathogenesis of the disease and to identify highrisk individuals. Together with more effective treatment modalities, this is essential to reach the ultimate goal, improvement of prognosis in diabetic patients.
The first part of this review summarised the role of the RAS in diabetic nephropathy and discussed specific genetic risk factors, especially Abstract Diabetic nephropathy is a major cause of diabetes related morbidity and mortality. The first part of the current review was published in the last issue of this journal and discussed the impotant role of the renin-angiotensin system (RAS) in diabetic nephropathy and the genetic influence on development of endstage renal disease (ESRD) in diabetic patients. This second part of the review focus on the potential improvement of the current treatment strategy to slow down the loss of kidney function using dual blockade of the RAS with both ACE-inhibitors (ACE-I) and angiotensin II receptor blockers (ARBs). Substantial evidence from short-term studies using surrogate endpoints indicates a beneficial impact of dual blockade of the RAS, not obtainable with single agent blockade alone, both in diabetic and non-diabetic renal disease. This conclusion has been confirmed and extended in a longterm trial with regard to prevention of ESRD in non-diabetic renal disease. Results indicate that dual blockade of the RAS may further slow down, but not arrest progressive loss of renal function. However, studies defining the optimal dose of ACE-I / ARBs without additional adverse effects are essential to ensure relevant comparison with dual blockade therapy. Trials using primary renal endpoints in diabetic nephropathy are still needed, and will finally establish the role of dual blockade of the RAS in a clinical setting. within the RAS, determining the individual rate of progression of kidney disease and response to treatment in diabetic nephropathy. This second part will discuss whether the current treatment strategy of RAS blockade in diabetic nephropathy with angiotensin-converting enzyme inhibition (ACE-I) or angiotensin II receptor blockers (ARBs) can be optimised by combining the two drug classes (dual blockade).
Dual Blockade of the Renin-Angiotensin System Rationale As previously discussed, antihypertensive treatment, especially blockade of the RAS, has had a tremendous impact on the prognosis in diabetic nephropathy, and ACE-I/ARBs have become first-line therapy in such patients. Unfortunately, the deleterious intrarenal processes continue to progress as this therapy delays, but does not prevent ESRD. 13 Since the generation of angiotensin II (Ang II) is a fundamental factor in both initiation and progression of diabetic kidney disease, alternative and more effective ways of blocking the RAS may offer clinical advantages. Dual blockade of the RAS means simultaneous treatment with both ACE-I and ARB to obstruct both the synthesis and activity of Ang II.
ACE-Is reduce the formation of Ang II by blocking the enzyme responsible for the conversion from angiotensin I ( Figure 1 ). Continued tissue or systemic generation of Ang II during ACE-I 25-28 might be explained by incomplete blockade of the ACE enzyme or by the production of Ang II by ACEindependent pathways, such as chymase. 29, 30 Upregulation of chymase has recently been reported in Type 2 diabetic patients with nephropathy. 31 In addition, ACE-Is decrease the degradation of bradykinin, a powerful vasodilator, 32 although the consequences of the increase in bradykinin levels in relation to renoprotection are not established. 33, 34 Angiotensin II receptor blockers antagonise the Ang II Type 1 (AT 1 ) receptor and may therefore interrupt the action of Ang II at a more rational point. Possible explanations of why ARBs do not offer complete blockade of the actions of Ang II include: 1) The compensatory increase in Ang II levels seen during treatment with ARBs may result in displacement of the ARB from the Type 1 receptor via competitive binding 2) Insufficient tissue concentrations of ARB in the receptor region 3) Ang II may exert its deleterious effects via pathways other than the AT 1 -receptor. The traditional assumption has been that activation of the Ang II Type 2 receptor (AT 2 ) results in many effects opposing the stimulation of the AT 1receptor, and therefore activation of the Type 2 receptor has been viewed as potentially desirable in cardiovascular and renal disease, as reviewed by de Gasparo 35 and Burns. 36 However, new data from animal studies indicate that the deleterious
Figure 1
The renin-angiotensin system* Compounds with genetic polymorphisms described in part I (Jacobsen PK, JRAAS 2005;6(1):1-14).
effects of Ang II on glomerular cell migration, tubular cell proliferation and development of urinary protein excretion are also, at least partly, mediated through the AT 2 -receptor 37-40 (see Figure 1 ). In addition, the AT 2 -receptor mediates apoptosis 35, 38 and production of vascular endothelial growth factor (VEGF), 41 which is potentially unfavourable. Recently, the Ang II type 4 receptor, stimulated by a metabolite of Ang II (angiotensin IV), has been suggested to be involved in renal sclerosis, as reviewed by Wolf, 42 Ma and Fogo. 43 This new information provides additional support to the concept that treatment with both ACE-I and ARBs may offer synergistic blockade of the RAS, not obtainable with either drug alone.
Animal Models
In a very elegant study performed in rats, Komine et al. 44 recently demonstrated that treatment with both ACE-I (captopril: 1.7 mg/day) and ARB (losartan: 0.7 mg/day) further reduces pulverised renal tissue Ang II levels compared with treatment with captopril (2.4 mg/day) or losartan (1.7 mg/day) alone. Furthermore, tripling the dose of captopril (7.5 mg/day) or losartan (6.0 mg/ day) did not reduce intrarenal Ang II to the level observed with low-dose dual blockade therapy. 44 This study demonstrates the synergistic effects of dual blockade of the RAS in renal tissue in animals, 44 although the method could miss regional renal differences in distribution of Ang II. Furthermore, the finding of a decline in renal Ang II during ARB treatment 44, 45 supports the idea of a renal/systemic dissociation in RAS activity, since circulating levels of Ang II are known to increase during ARB treatment. Several studies have looked at the therapeutic efficacy of dual blockade therapy on BP and urinary protein excretion in different experimental models. Data from reduced renal mass models in rats showed conflicting results. [46] [47] [48] In diabetic spontaneously hypertensive rats, a model of diabetic nephropathy 49 and in a model of Heymann nephritis 50 dual blockade of the RAS had superior anti-proteinuric 49, 50 and BPlowering effects 49 compared with monotherapies.
Studies in spontaneously hypertensive rats demonstrated additive effects on the decline in BP. 51, 52 A recent study of rats with adriamycininduced nephrosis addressed the important question of whether dual blockade treatment could turn individuals with a poor response to ACE-I into good responders. 53 This study revealed that addition of ARB did not improve the antiproteinuric response to ACE-I, either in the whole group or in the subgroup with a poor initial response to ACE-I: poor-responders remained poor responders. 53 In contrast, in an elegant study of rats, Remuzzi et al. 54 demonstrated for the first time that dual blockade therapy can not only lower BP, albuminuria and halt the progression of structural kidney changes, but also induces some degree of regression in sclerosis, collagen accumulation and inflammation in addition to normalising protein excretion and blood pressure. The study did not compare dual blockade with monotherapy, but the results support the very interesting concept of reestablishment of lost kidney function/structure in response to effective RAS blockade.
In summary, studies of the effect of dual blockade of the RAS in experimental models show conflicting results, although there is a majority of papers showing positive effects of dual blockade therapy compared with monotherapy. Differences in the results are possibly a consequence of differences in the dose of drugs used and in the animal models under investigation. Furthermore, it should be stressed that fundamental discrepancies exist between the RAS in man and rodents. 55
Renal Disease in Humans
In parallel with the results from animal models, information from human studies has become available. In contrast to the animal studies, which primarily focused on pathophysiologic processes, human studies have taken a more clinical approach, and focused on whether dual blockade, irrespective of the underlying mechanisms, provides more end organ protection. The vast majority of reports have looked at the short-term (< 3 month) effects of dual blockade treatment.
The first human studies of dual blockade therapy were carried out in normal subjects and showed an additional BP-lowering effect as compared with ACE-I. 56, 57 The first real manifestation of the new treatment concept was the results of the CALM study, 58 a prospective, randomised, doubleblind study of 199 Type 2 diabetic patients with microalbuminuria and hypertension. This study found an enhanced reduction in BP of 10/6 mmHg (systolic/diastolic) and a tendency towards a more pronounced drop in urinary albumin excretion by 12 weeks dual blockade (candesartan cilexetil 16 mg and lisinopril 20 mg) compared to therapy with either agent alone. 58 Encouraged by the CALM study, we made the first short-term trial with dual blockade of the RAS in Type 1 diabetic patients with diabetic nephropathy. 59 
by the same criteria using identical design and methods. 60 Since the subgroup participating in our first study may differ from typical patients with diabetic nephropathy, especially with regard to RAS activity and sensitivity to blockade of the system, we designed a new trial performed in a representative group of Type 1 patients with diabetic nephropathy. 61 In addition, a placebo period was included, making direct comparisons of the effects of mono-and combination therapy possible. 61 In this study, the design was a randomised, double-blind, cross-over trial, in which the 18 patients received placebo, or benazepril 20 mg once daily, or valsartan 80 mg once daily or the combination of benazepril 20 mg and valsartan 80 mg once daily in random order. The length of each treatment period and methods for evaluations of treatment effects were the same as in the first study. 59 Key findings were ( Figure 2 ) monotherapy with ACE-I or ARB treatment was equally effective with regard to antialbuminuric and antihypertensive effects. 2) Short-term dual blockade of the RAS caused a further reduction in albuminuria of 43% and 7/6 mmHg in blood pressure compared with either monotherapy. 3) GFR was reversibly reduced by dual blockade of the RAS. 61 As can be seen, this study confirmed and extended the findings from our initial study. In contrast to the three above-mentioned studies carried out at Steno Diabetes Center, Parvanova et al. 62 did not find an additional effect of dual blockade compared with ACE-I in 39 hypertensive Type 2 diabetic patients with diabetic nephropathy. However, this study compared combination therapy with ACE-I (enalapril 10 mg) and ARB (losartan 50 mg) with monotherapy using double these doses. 62 The three therapies had similar antihypertensive effects; enalapril and dual blockade had equal antiproteinuric effects, although both were superior to losartan. 62 Because of the halving of doses, the study investigated the synergistic and not the superior effect of dual blockade of the RAS. This is a very relevant observation, but should not lead to unnecessary disqualifying of the new treatment concept. In various non-diabetic renal diseases, superior effects of dual blockade compared with single blockade were reported in several short-term, open-labelled studies. [63] [64] [65] [66] [67] [68] [69] 
Dosing of ACE-I/ARB
The above-mentioned papers have all reported on the effect of combining sub-maximal doses ACE-I and ARB. This is a fundamental limitation, since all the studies carry the risk of underestimating the effect of monotherapy with ACE-I and therefore favouring dual blockade therapy. In our initial trials, we selected the standard ACE-I doses used in treatment of diabetic nephropathy as monotherapy, namely enalapril/lisinopril 20 mg or captopril 100 mg daily 59, 61 This is equal to or higher doses than recommended based on studies documenting the renoprotective effect of the drug. 14, 16 However, to overcome the limitations of the former studies, we conducted the first trial in Type 1 diabetic patients with diabetic nephropathy in which dual blockade therapy was compared with the maximal recommended dose of ACE-I. 70 In a randomised, double-blind, crossover trial of 24 representative Type 1 patients with diabetic nephropathy, placebo or irbesartan, 300 mg once daily, was added to a usual antihypertensive regime, including enalapril 40 mg daily. Other methods were as in the previous studies. 59, 61 Again, we saw an additional reduction in albuminuria of 25% and a decline in BP of 8/4 mmHg when adding the ARB to the maximal recommended dose of ACE-I 70 (Figure 3 ). In 20 Type 2 patients with diabetic nephropathy, we applied an identical design, and found that dual blockade caused a reduction in albuminuria of 28% and a non-significant drop of 2-3 mmHg in both systolic and diastolic BP. 71 Very few other studies have made a fair comparison using the 
highest obtainable degree of ACE-inhibition as a reference: Agarwal 72 reported that adding 50 mg of losartan daily to 40 mg of lisinopril daily had no effect on BP and proteinuria in a heterogeneous group of 16 predominantly severe obese, hypertensive, proteinuric diabetic Afro-Americans with advanced renal failure. Surprisingly, a lowered plasma renin activity and enhanced GFR during losartan + ACE-I was also reported in the same study. 72 An increase in plasma renin is a fundamental observation seen with all types of RAS blockade in other populations and are accepted as a measure of the extent of blockade. Therefore, racial differences in RAS activity and response to RAS blockade makes extrapolation to other ethnic groups impossible. 73, 74 Additional limitations of the study by Agarwal 72 includes under-dosing with losartan, since 100 mg is more effective than 50 mg on both albuminuria and blood pressure in diabetic nephropathy. 75 77 see Figure 4 . The beneficial effects of combination therapy were found despite equal BP control in the three groups, obtained with other antihypertensive drug classes. Very importantly, and supporting the short-term studies, the trial confirmed the superior antiproteinuric influence of dual blockade of the RAS with an extended observation period. Prior to randomisation, the dose of 3 mg trandolapril was chosen, since uptitration to 6 mg trandolapril daily had shown no further impact on proteinuria. 77 Even though we used the maximal recommended doses of both ACE-I and ARB in our last trials 70, 71 we can not completely exclude the possibility of under-dosing with both agents. Unfortunately, the optimal doses of ACE-I and irbesartan are not well defined; there is a lack of dose-escalation studies of the antiproteinuric and antihypertensive effects of enalapril/lisinopril >20 mg or irbesartan >300 mg daily in patients with diabetic nephropathy. From studies in patients with moderateto-severe essential hypertension, we found no evidence of an additional antihypertensive effect of doses of captopril up to 600 mg, enalapril/ benazepril up to 80 mg [78] [79] [80] [81] or irbesartan up to 900 mg. 82 However, the dissociation between systemic and intrarenal RAS may result in different optimal doses of ACE-I/ARBs on systemic blood pressure and albuminuria, as seen in Type 2 diabetic patients with nephropathy. 83 In accordance, a small study in patients with nondiabetic kidney disease has indicated additional anti-proteinuric, but not antihypertensive effects of lisinopril 40 mg daily compared with lower 
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tension. This is not seen in Type 2 patients. In the majority of cases, symptoms disappear within two weeks. Based on existing data, it is not possible to predict in whom the symptoms will occur. 2) Plasma potassium increases by ~0.3 mmol/L independent of the doses used. This has little clinical significance unless GFR is less than 40 ml/minute/1.73m 2 , where a small fraction of the patients experience a clinically relevant elevation in plasma potassium requiring intervention.
3) In one study, we saw a significant, but reversible decline in GFR of 7 ml/minute/1.73m 2 compared with monotherapy. 61 None of the patients experienced an increase in plasma creatinine of more than 30%. The initial decline in GFR with RAS blocked is a well described phenomenon 87 and a large decline predicts a subsequent more stable renal function in diabetic and nondiabetic renal disease. 87, 88 Furthermore, studies in diabetic 89 and non-diabetic renal disease 88 have shown that the initial fall in GFR after starting antihypertensive treatment is reversible even after years of treatment. This indicates a relationship to the drop in systemic BP transmitted to the renal micro-vasculature. 4) Haemoglobin decreases by ~0.3 mmol/L in Type 1 diabetic patients. Renal erythropoietin (EPO) synthesis is stimulated by Ang II 90,91 via the Type 1 receptor 92 and a correlation between decline in haemoglobin and decline in EPO levels during dual blockade of the RAS has been demonstrated in non-diabetic renal disease. 93 5) The RAS is an important and powerful regulator of vascular volume and pressure homeostasis. In doses. 76 On the other hand, the COOPERATE trial 77 of Japanese patients with non-diabetic renal disease reported a short-term anti-proteinuric efficacy of 3 mg trandolapril daily equal to 6 mg daily. It is essential that well designed doseescalation studies with ACE-I/ARBs above the standard doses are carried out to define the most effective therapy in diabetic nephropathy.
All the short-term studies, including our own, have evaluated the impact of dual blockade of the RAS on surrogate parameters after 1-3 months treatment. This is in accordance with our own and other studies demonstrating maximal antiproteinuric and antihypertensive effects within four weeks after starting treatment with ARBs in diabetic 84, 85 and non-diabetic kidney disease. 86 In addition, the COOPERATE trial found that once ARB or dual blockade treatment reached a plateau after dose titration, proteinuria remained constant for the rest of the three years of followup, whereas ACE-I treated patients tendency towards increasing proteinuria. 77 
Adverse and Side Effects
All studies powered for assessing the tolerability of dual RAS blockade have shown it to be a safe treatment regime, with no more adverse effects than ACE-I therapy alone. 58, 63 In addition, our experiences with dual blockade in patients with diabetic nephropathy 59-61,70,71 adds the following: 1) Fifteen to 30% of Type 1 patients describe transient discomfort/tiredness/signs of hypo- In the three studies of Type 1 patients, we found a consistent tendency towards a lowering of plasma total cholesterol and LDL-cholesterol of ~0.3 mmol/L compared with ACE-I. 59, 61, 70 When pooling data from all three studies the change in both plasma total cholesterol and LDL-cholesterol of 0.3 mmol/L were statistically significant (p=0.01). In accordance with previous reports, 94, 95 the finding was also seen with ARB treatment alone, although to a lesser degree. 61 This suggests a relationship between the degree of blockade of the RAS and decline in albuminuria, in accordance with results in patients obtaining reversal of nephrotic syndrome. 96 If the results are confirmed, a beneficial impact of dual blockade on lipid profile may further contribute to longterm renal and cardiovascular protection.
In summary, if contraindications to ACE-I/ARBs treatment are respected, dual blockade of the RAS is safe and well tolerated. Plasma potassium should be monitored two weeks after commencing therapy in all patients and subsequently in patients with impaired renal function (GFR < 40 ml/minute/1.73m 2 ). Symptoms of hypotension are related to the BP-lowering effect not specific to this therapy.
Underlying Mechanisms in Man Is the benefit from dual blockade therapy due to a greater blood pressure lowering effect or does this therapy offer an intrinsic form of renoprotection?
The COOPERATE trial clearly demonstrated an effect on both albuminuria and doubling of screatinine/ESRD independent of BP-lowering in non-diabetic renal disease. 77 Similar findings come from several of the open-labelled studies, although they all 65,67,76 but one 69 show insignificant tendencies towards more BP suppression with dual blockade therapy, making interpretation difficult. The design of our own studies does not allow us to distinguish between a specific antiproteinuric effect of dual blockade of the RAS and the effect of lowering BP in diabetic patients. 59, 61, 70 Until a head-to-head comparison between monotherapy and dual blockade reaching identical BP levels, like the COOPERATE trial, 77 is made, this issue in diabetic nephropathy will remain unsolved. We found correlations between changes in BP and changes in albuminuria in all our studies 59, 61, 70 and in one study we made a multiple model correcting for the change in BP, resulting in the disappearance of treatment effect of dual blockade on albuminuria. 70 These observations do not rule out a BP-independent effect, but emphasise the fact that dual blockade therapy is effective on both parameters and that individual susceptibility to lowering of albuminuria and BP are related in Type 1 diabetic patients with nephropathy. Information supporting a BP-independent effect of dual blockade therapy comes from the studies of monotherapy with ACE-I/ARB versus other types of antihypertensive therapy in Type 1 patients with nephropathy 16, 97 and Type 2 patients with elevated urinary albumin excretion. [98] [99] [100] From a clinical point of view, the discussion of a BPindependent effect is probably of less importance; both reduction in BP and in albuminuria are essential treatment goals in diabetic patients with kidney disease and powerful multiple drug therapies are often needed to reach treatment goals. Based on rough estimates from studies in diabetic nephropathy, 15 the mean BP reduction of ~5 mmHg demonstrated in our three studies may result in preservation of ~2 ml/minute/year in GFR. In addition, a recent meta-analysis in Type 2 diabetic patients 101 demonstrated ~30% reduction in cardiovascular death or myocardial infarction as a response to comparable BP reductions.
In addition to renal haemodynamic changes, the superior effect of dual blockade on albuminuria may be caused by alterations in the permeability of the glomerular basement membrane. Monotherapy with ARBs has been shown to improve the defect in size selectivity in Type 1 patients with diabetic nephropathy, although this did not completely account for the beneficial effects on albuminuria. 102 Other alterations in the basement membrane modulated by dual blockade of the RAS may include altered charge and shape selectivity. 103, 104 On the other hand, a recent study in non-diabetic kidney disease has indicated an association between the reduction in urinary protein : creatinine ratio and increased renal plasma flow, but did not indicate changes in size selectivity of the basement membrane during dual blockade therapy. 69 Several of the studies evaluating dual blockade treatment also directly compared the effects of ACE-Is and ARBs. ACE-Is, in standard doses, are at least as effective as ARBs on renal vascular responses in early diabetes, 69,105 on reduction in urinary albumin excretion and BP in diabetic 58, 61, 94, 106, 107 and non-diabetic renal disease. 69, 77, 108 This indicates that the majority of Ang II is generated by the ACE enzyme and that chymase pathway plays a minor functional role in the diabetic kidney. In agreement, we found a very similar plasma renin response to ACE-I or ARB treatment and a further increase on dual blockade therapy. 61 The increase in plasma renin during RAS blockade indicates more complete Ang II blockade, due to inhibition of the negative feedback in the kidney. 36, 109 The close co-variation between renin and albuminuria/blood pressure seen in our studies 59 70, 71 In contrast, the antialbuminuric response was equal in both types of diabetes, suggesting that diabetic nephropathy in Type 2 diabetes is primarily characterised by intrarenal RAS activation. This is in agreement with an extensive renal vascular response to ARBs, despite a low baseline plasmarenin activity in Type 2 patients with diabetic nephropathy. 109
Individual Responses
As seen with respect to the decline in GFR and time to ESRD in diabetic nephropathy, we found a large variation in individual response to dual blockade of the RAS. Analysing data from our three studies in Type 1 patients together (defined as total cohort, n=51), 59, 61, 70 we saw an antialbuminuric range from no response to a reduction of 87% as compared with monotherapy with ACE-I. The obvious question from a clinician's point of view is whether we can predict who will become good-responders and who will not.
When looking at the total cohort or the individual studies, the only baseline characteristics/parameter predicting the antialbuminuric response to dual blockade was RAS polymorphisms. In the total cohort, patients carrying the D allele (ACE/ ID) had a significantly poorer response (mean 31 [95% CI 16 to 43] %) compared with patients with the II genotype (55 [35 to 69] %), p=0.021. This was even more pronounced in the study using maximally recommended doses of ACE-I, 70 in which DD patients had a drop in albuminuria of 10 (-18 to 32) % compared with 57 (21 to 76) % in II patients, p=0.010 (not published), but interpretation should be made with caution owing to the small number of patients. The findings are in agreement with our earlier findings of the relationship between the ACE/ID polymorphism and the reduction in albuminuria after the start of ACE-I treatment 110 and progression of diabetic nephropathy. 13, 111 In contrast, in a comparable group of patients there was a similar short-term antialbuminuric effect of ARB treatment in patients with II versus DD genotype. 112 The underlying mechanisms needs further investigation but, as discussed in part I, ( Jacobsen PK, JRAAS 2005;6(1):1-14). ACE-I therapy may reinforce the differences between ACE/ID genotypes, due to increased local/systemic production of ACE.
We also saw a trend towards an influence of the Ang II Type 1 receptor polymorphism (A 1166 ->C) on reduction in albuminuria: In the total cohort, albuminuria in patients with the AA genotype declined by 28% (3 to 46%) compared with 49% (34 to 60%) in patients with the AC or CC genotype, p=0.07 (not published). The power of the study was insufficient to look at genetic interactions between the M/D/A alleles.
The antihypertensive effect was not related to the genetic composition, but a more pronounced effect was seen in patients with higher baseline BP. We found a tendency towards a more pronounced antihypertensive effect in men, but this was explained by a higher baseline BP.
We showed a strong correlation between the individual changes in surrogate parameters on monotherapy and dual blockade, 61 although more pronounced on the latter. This is in accordance with a previous study comparing individual reductions in proteinuria after start of ACE-Is and ARBs in diabetic and non-diabetic nephropathy. 113 In our study, the fraction of patients with the poorest antialbuminuric response to ACE-I (below the median) still obtained a significant drop of 37% in albuminuria and ~7 mmHg in diastolic BP on dual blockade therapy, compared with ACE-I (based on results from, 61 not published). In other words, our study suggests that poor responders to ACE-I will also gain significant benefit from dual blockade therapy. This is in contrast to findings in an animal model, which indicated that poor responders to ACE-I remain poor responders after addition of ARBs. 53
Conclusions
Substantial evidence from short-term studies using surrogate endpoints indicates a beneficial impact of dual blockade of the RAS, not obtainable with monotherapy, both in diabetic and non-diabetic renal disease. This conclusion has now been confirmed and extended in a long-term trial with regard to prevention of ESRD in non-diabetic renal disease. Results indicate that dual blockade of the RAS may further slow down, but not arrest the progressive loss of renal function. However, studies defining the optimal dose of ACE-I without additional adverse effects are essential to ensure relevant comparison with dual blockade therapy. Trials using primary renal endpoints in diabetic nephropathy are still needed, and will finally establish the role of dual blockade of the RAS in a clinical setting.
The individual response to dual blockade therapy is variable. It seems as the effect is influenced by the same genetic polymorphisms in the RAS as the long-term prognosis during ACE-I treatment.
In our relatively small studies, patients carrying the II genotype of the ACE/ID polymorphism (and the C allele of the Ang II Type 1 receptor [A 1166 ->C]) were particularly sensitive to dual blockade of the RAS. It should be emphasised that the relationship needs further confirmation in larger studies. Apart from this, all sub-groups of patients with diabetic nephropathy seem to benefit from dual blockade therapy, even patients with a poor response to ACE-I. However, patients with the most pronounced albuminuria and elevated BP have the highest associated morbidity and mortality and consequently these patients will also gain the most benefit for treatment.
Other Cardiovascular Diseases in Humans
Finally, the effect of dual blockade of the RAS on cardiovascular endpoints apart from the kidney deserves a few remarks. Although this is not within the primary scope of this review, renal and cardiovascular diseases are frequently bad companions, especially in diabetic patients. In addition, activation of the RAS is now thought to be the common pathway involved in processes leading to several end organ diseases such as atherosclerosis, ESRD, stroke and heart failure in high-risk individuals. In agreement, the HOPE study demonstrated the beneficial effect of ACE-I treatment on several cardiovascular endpoints in various high-risk patients. 114 Apart from the antihypertensive effect seen in patients with renal disease, dual blockade of the RAS has shown promising results in the treatment of essential hypertension, 115, 116 although the studies carry a risk of bias due to under-dosing of ACE-I (see above). In patients with heart failure, dual blockade therapy reduced pulmonary and systolic BP 117 and in severe heart failure, addition of an ARB to maximal obtainable ACE-I improves exercise capacity. 118 In the RESOLVD study, 43 weeks treatment with dual blockade therapy lowered BP and improved surrogate endpoints of cardiac function in 768 patients with heart failure. 119 The Val-HeFT trial investigated 5,010 patients with chronic heart failure, followed for 1.9 years after the addition of ARB to standard ACE-I therapy. 120 Dual blockade treatment had no effect on all-cause mortality, but an impact on combined all-cause mortality and morbidity was demonstrated (relative risk ~0.76). 120 Post hoc analysis raised doubt about the safety of combining dual blockade with betablockers in chronic heart failure. 120 Recently, the CHARM study demonstrated a statistically significant reduction in cardiovascular death or hospital admission for chronic heart failure (hazard ratio 0.85, p=0.01) when candesartan was added to ACE-I in a study of 2,500 patients with heart failure and an ejection fraction of 40% or less followed for 41 months. 121 The CHARM study also demonstrated beneficial effects of adding candesartan to ACE-I in patients treated with beta-blockers. 121 The ONTARGET study is a very large ongoing trial of more than 20,000 patients with increased risk of cardiovascular events (similar to the HOPE study). ONTARGET will test whether dual blockade therapy reduces atherosclerotic events and their sequelae. Secondary endpoints include the development of nephropathy.
Future Strategy for Optimal RAS Blockade
Experiences with ACE-I and ARBs and their combination suggest that further optimising local and systemic RAS blockade is a beneficial goal and that this might be possible without unacceptable adverse effects.
Monitoring Intrarenal RAS Activity
The extent of albuminuria at any stage may be a very good marker of renal prognosis. However, a fundamental limitation in the studies of renoprotection is the current lack of specific methods for monitoring activity of the intrarenal RAS in humans. Such a possibility would be very helpful to understand pathogenesis, to monitor the early stages of diabetic nephropathy before elevated urinary albumin excretion develops and to evaluate treatment efficacy in all stages of the disease. Efforts should be made to develop such a reliable method. Very interesting experimental results from Kobori et al. [122] [123] [124] have suggested that urinary excretion of angiotensinogen reflects intrarenal angiotensinogen and RAS activity.
Other possibilities are urinary excretion of Ang II or TGF-ß.
An alternative approach is to screen for potential markers of intrarenal RAS after stimulation or suppression of the RAS. Stimulation/suppression could be done by change in sodium intake (high sodium will inhibit the RAS, whereas low sodium will activate it) or RAS blockade. Screening for changes in the levels of a large amount of known and unknown urinary proteins could be performed by new techniques, such as proteomic analysis. 125 
Dose Intervals in ACE-I and ARB Therapy
Until now, we have assumed sufficient 24-hour coverage of drugs used for RAS blockade. Determinations of the duration and efficacy following administration of a single dose of ACE-I and ARBs are based on evaluation of BP and/ or systemic drug levels with time. As described, dissociation between systemic and renal RAS activity exists in diabetic nephropathy. It is not known whether intrarenal RAS blockade is optimal after a single dose or if the time of administration is important. Nakao et al. 126 have demonstrated that administration of ACE-I at night time lowered albuminuria more than the same therapy taken in the morning in non-diabetic renal disease. The subject deserves further attention.
Specific Renal Delivery of RAS Blockade
If the level of intrarenal RAS blockade needs to be higher than systemic RAS blockade, and if adverse effects are related to the systemic RAS blockade, specific renal delivery of ACE-I or ARBs could offer advantages. Finding ways of transporting inactive forms of the drugs to renal compartments where they will be activated is an elegant strategy. Haverdings et al. 127 developed a method, by which the ACE-I, captopril, is conjugated to low-molecular-weight protein, lysozyme, which accumulates specifically in proximal tubule cells. When administered to rats, renal haemodynamic effects were more pronounced compared with captopril as a free drug, without systemic effects. 127 More importantly, rats with renal disease had a more extensive antialbuminuric response to captopril-lysozyme than to free captopril. 127, 128 Review 
New Renoprotective Drugs
Interrupting the RAS by blocking other components in addition to the ACE enzyme and/ or the AT 1 -receptor is another obvious approach. Growing evidence suggests that aldosterone, in addition to Ang II, is an important pathogenetic factor in progressive renal disease. [129] [130] [131] Reduction in aldosterone levels are suggested to account for part of the effects of blocking Ang II formation. 129 Since aldosterone remains elevated despite treatment with ACE-I and/or ARBs 119, 132, 133 there is a theoretical rationale for aldosterone antagonism. The addition of aldosterone blockers to ACE-I or ARBs has been demonstrated to lower systolic BP in patients with essential hypertension 134 and an antialbuminuric effect of spironolactone in patients with diabetic and non-diabetic kidney disease treated with ACE-I was indicated in two small studies. 133, 135 These preliminary data are exciting, but the subject needs further investigation in diabetic nephropathy.
Vasopeptidase inhibitors are a new class of cardiovascular drugs that simultaneously inhibit both neutral endopeptidase (NEP) and the ACE enzyme. 136 As a consequence, they both increase the availability of peptides that have vasodilatory and other potential beneficial vascular effects, in addition to inhibiting the Ang II formation. 136 Omapatrilat, a member of this new drug class, has been demonstrated to provide at least equal BP-lowering efficacy to ACE-I and other antihypertensive agents. 136 In subtotally nephrectomised rats, omapatrilat has been shown to offer superior short-term and long-term renoprotection compared with ACE-I therapy. 137, 138 No human data in kidney diseases are currently available. Concerns over adverse effects have halted the original optimism for this drug, since data from the Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE) Trial, including 25,000 patients with hypertension, has demonstrated an incidence of angio-oedema of 2.17% with omapatrilat compared with 0.68% with enalapri. 139 If identification of patients with low risk of angio-oedema is possible, this new treatment may offer advantages and should be tested in renal diseases, including diabetic nephropathy.
Conclusions and Clinical Applications
The development of diabetic nephropathy has very serious consequences in the majority of patients. The renal prognosis and survival has improved significantly in patients with diabetic nephropathy, but the disease has a highly variable course among individuals, and diabetic nephropathy is still the most frequent cause of ESRD worldwide. Activation of the RAS has a causal role in processes leading to destruction of the diabetic kidney. Loss of kidney function and the treatment efficacy of established renoprotective therapy with ACE-I are dependent of individual genetic and non-genetic characteristics. Focus on these differences is likely to diminish the variability in therapy response and may therefore improve the overall prognosis.
Albuminuria, BP, metabolic control and cholesterol are established non-genetic risk factors. In addition, short-term hyperglycaemia may induce a modest increase in systemic BP linking haemodynamic and non-haemodynamic factors.
There is also convincing evidence of genetic components influencing the decline in kidney function. The ACE/ID polymorphism in the gene coding for the ACE enzyme independently affects the treatment response to ACE-I and may interact with other polymorphisms in the RAS, resulting in poorer renal prognosis. Genotyping therefore offers a new tool to identify individuals at risk for early ESRD and specific therapy to these patients needs to be developed. Until then, aggressive treatment of other risk factors is particularly important in patients carrying the genetic variants associated with poor renal prognosis. However, the ultimate goal, a reliable prediction of the course of diabetic nephropathy in the individual patient, has not yet been reached. The search for specific genetic alterations with an impact on diabetic nephropathy is limited by current insufficiency in knowledge and methods. However, a rapid development of methods and new information from the completion of the draft sequence of the human genome will change this in the near future.
Further arresting the destruction of renal function can be obtained by more effective blockade of the RAS. Reduction in albuminuria and BP are short-term treatment goals for subsequent stabilisation of renal function and improved survival. Dual blockade of the RAS using ACE-I and ARBs seems to be one way of preserving kidney function in diabetic nephropathy. In three short-term studies, we have demonstrated that dual blockade therapy is safe and superior to conventional renoprotective treatment with ACE-I alone. However, long-term trials will finally define the potential of this new treatment concept in diabetic nephropathy. Experimental evidence suggests that sufficient RAS blockade by ACE-I and ARBs may terminate the destructive processes or even repair underlying structural changes, resulting in stable or improved kidney function and ultimately prevention of ESRD.
In the clinical setting, an individual treatment strategy, based on evaluation of genetic and non-genetic risk factors, should be performed. Normalising urinary albumin excretion and BP are primary goals in the patient with diabetic nephropathy and titration of antihypertensive therapy against both parameters is essential. In addition, other factors are known to intensify the renoprotective effects of RAS blockade and 
